Key result
IVCF in cancer-associated thromboembolism linked to ~80% lower PE mortality but higher recurrences.
Why the study?
The association between inferior vena cava filter use and outcomes in patients with cancer-associated thromboembolism and contraindications to anticoagulation remains unclear.
Does inferior vena cava filter insertion improve outcomes in patients with cancer-associated thromboembolism and contraindications to anticoagulation?
Cohort (n=17,005)
Does inferior vena cava filter insertion improve outcomes in patients with cancer-associated thromboembolism and contraindications to anticoagulation?
Absolute Event Rate: 12.2% vs 17%
p-value: p=0.13
In patients with cancer-associated VTE and contraindications to anticoagulation, IVC filters may reduce PE-related mortality at 30 days but are associated with an increased risk of recurrent thromboembolism.
Background The association between the use of inferior vena cava filters (IVCFs) and outcomes among patients with cancer-associated thromboembolism (CT) and contraindications to anticoagulation remains unclear. Methods In this prospective cohort study of patients with CT from the Registro Informatizado de la Enfermedad TromboEmbólica Registry, we assessed the association between IVCF insertion due to contraindication to anticoagulation and the outcomes of all-cause mortality, pulmonary embolism (PE)-related mortality, recurrent thromboembolism, and major bleeding rates through 30 days after initiation of treatment. We used propensity score matching to adjust for the likelihood of receiving a filter. For outcomes assessment, we implemented generalized estimating equation methods to incorporate the matched-pairs design, and adjusted for covariates that remained unbalanced after matching. Results Of the 17,005 patients with CT, 270 underwent IVCF placement because of contraindication to anticoagulation. Of those, 247 were successfully matched with 247 patients treated without a filter. Propensity score-matched pairs showed a nonsignificantly lower risk of all-cause death (12.2% vs. 17.0%; p = 0.13), and a significantly lower risk of PE-related mortality (0.8% vs. 4.0%; p = 0.04) for patients receiving IVCFs compared with those who did not. While there was no significant difference in the rate of major bleeding (6.1% vs. 5.7%; p = 0.85), risk-adjusted recurrent rates were higher for patients who received IVCFs compared with those who did not (7.3% vs. 3.2%; p = 0.05). Conclusion In patients with CT and a contraindication to anticoagulation, IVCF insertion was associated with a lower risk of PE-related death, and a higher risk of recurrences.
No takes yet. Share an insight, caveat, or question.
Quezada et al. (2020) conducted a cohort in Cancer-associated venous thromboembolism with contraindications to anticoagulation (n=17,005). Inferior vena cava filter (IVCF) insertion vs. No filter was evaluated on All-cause mortality (p=0.13). Inferior vena cava filter insertion in patients with cancer-associated thromboembolism was associated with lower PE-related mortality (0.8% vs 4.0%; p=0.04) but higher recurrences (7.3% vs 3.2%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: